Investor Presentaiton
AROA at a Glance
Well established high-growth soft tissue regeneration company
JE
NZ$30-33m
product sales forecast for
FY221
68% Gross Margin
FY21, impacted by lower sales
and FX
TIT
6 patented
product families
selling in United States
Regulatory
Approvals
in 49 countries
32
三回
Peer Reviewed Publications
$
-mm-0
>US$2.5b² TAM
88
for existing products
4 million+
Procedures with
AROA's products
AROA ECM™
platform
Provides new products and line
extensions year on year
~170
personnel³
1. Guidance subject to no resurgence of COVID-19 in the US, continued improvement in US medical procedure numbers & TELA Bio sales performance. It assumes an average $NZD-$USD exchange rate of US$0.72
2. SmartTRAK Biomed GPS data 2020; DRG Millennium Research data; Hernia Repair Devices, 2020, AROA management estimates; DRG Millennium Research, Breast Implants & Reconstructive devices, 2018
Market data was prepared before the onset of COVID-19, the economic effect of which is currently not possible to predict with any certainty. Consequently, while the Company has no reason to believe that the
market data does not remain accurate based on the relevant markets operating normally, the impact of COVID-19 on the market data that is referenced is not possible to currently predict with any certainty and
investors are cautioned against placing undue reliance on such data.
3. AROA NZ & US employees.
AROA
TM
5View entire presentation